Featured image: A laboratory microscope illustrates cancer research. Contextual image; not visual evidence of the specific study, treatment, project or facility. Photo: Ousa Chea. Unsplash licence.
A drug combination aimed at two linked cancer vulnerabilities has produced an unusually high early response rate in a narrow group of people with metastatic pancreatic cancer. Data reported at the European Society for Medical Oncology congress showed that 18 of 22 response-evaluable participants, or 82%, had tumours shrink enough to meet the study’s objective-response definition. Investor’s Business Daily reported the 23 October results from the ongoing Tango Therapeutics Phase I/II study.
The number deserves attention, but not a victory lap. Twenty-two people in a non-randomised, early-stage study are not enough to establish that the combination helps patients live longer, works better than existing care or has a tolerable risk profile across a larger population. The medicines remain investigational.
The combination targets RAS signalling and an MTAP-linked weakness
Daraxonrasib is designed to inhibit active forms of RAS, a family of proteins that can drive cancer growth when mutated. Vopimetostat inhibits PRMT5, an enzyme involved in gene regulation and RNA processing. The trial selects tumours that both carry a RAS mutation and have lost MTAP, a neighbouring gene whose absence can make cancer cells unusually dependent on PRMT5.
That pairing creates a biological rationale: suppress the main growth signal while exploiting a second vulnerability associated with MTAP deletion. It does not prove synergy in people. A combination can look better because of patient selection, small numbers, the activity of one component or chance unless it is compared with an appropriate control.
Objective response is useful but incomplete
Objective response rate, or ORR, is the proportion of evaluable patients whose tumours shrink by a predefined amount on scans. It can provide an early signal in advanced cancer, especially when responses are uncommon with current therapy. ORR does not directly measure symptom relief, overall survival or whether the benefit outweighs toxicity.
The updated dataset reportedly had a 20 August 2026 cutoff and included second- or third-line patients with MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma. The company also reported that 88% were progression-free at nine months, while median progression-free survival had not yet been reached. Those estimates can change substantially as follow-up lengthens and more events occur.
Earlier company data released in June described 11 responses among 12 evaluable pancreatic-cancer participants, or 92%, at a May cutoff. The percentage falling to 82% as the group grew is not necessarily deterioration; it illustrates why very small denominators are volatile. The current result is based on more patients, but it remains an early snapshot.
Safety must be judged alongside shrinkage
Tango’s June report said most treatment-related adverse events at the selected lower dose were grade 1 or 2, while thrombocytopenia—low platelets—was among the grade 3 events. Higher-grade events matter because they can lead to dose interruptions, hospital care or bleeding risk. The larger safety population and longer follow-up are therefore as important as the response count.
The company’s clinical-trial overview describes the combination as part of an ongoing dose-escalation and expansion programme. Phase I portions chiefly establish dose and safety; Phase II portions look for an efficacy signal in selected patients. Neither stage substitutes for a confirmatory randomised trial.
A Phase III plan would ask the decisive question
Tango’s 16 October congress preview said updated data would inform a registration strategy. The company has discussed a planned frontline Phase III trial, but a plan is not an enrolled trial and certainly not a result. A randomised design would need to compare the combination against an accepted treatment, use predefined endpoints and include enough participants to distinguish a real effect from selection and chance.
The 82% response rate is one of the more compelling early pancreatic-cancer signals reported this year. The scientifically responsible conclusion is also the narrow one: the combination has earned a rigorous comparative test. It has not yet shown that it improves survival, and it has not cured pancreatic cancer.
Reporting and source checks completed on 23 October 2026. By FutureTechDose Editor.
Leave a Reply